RS67141B1 - Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije - Google Patents

Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije

Info

Publication number
RS67141B1
RS67141B1 RS20250816A RSP20250816A RS67141B1 RS 67141 B1 RS67141 B1 RS 67141B1 RS 20250816 A RS20250816 A RS 20250816A RS P20250816 A RSP20250816 A RS P20250816A RS 67141 B1 RS67141 B1 RS 67141B1
Authority
RS
Serbia
Prior art keywords
bruton
treatment
tyrosine kinase
kinase inhibitor
chronic spontaneous
Prior art date
Application number
RS20250816A
Other languages
English (en)
Inventor
Souvik Bhattacharya
Bruno Bieth
Maciej Cabanski
Bruno Cenni
Buck Stefan De
Martin Kaul
Arvind Kinhikar
Andrijana Radivojevic
Thomas Severin
Julian Storim
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS67141B1 publication Critical patent/RS67141B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20250816A 2019-05-23 2020-05-20 Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije RS67141B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
EP20729204.6A EP3972604B1 (en) 2019-05-23 2020-05-20 A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria

Publications (1)

Publication Number Publication Date
RS67141B1 true RS67141B1 (sr) 2025-09-30

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250816A RS67141B1 (sr) 2019-05-23 2020-05-20 Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije

Country Status (22)

Country Link
US (2) US12419889B2 (sr)
EP (2) EP4599894A3 (sr)
JP (2) JP7568651B2 (sr)
KR (1) KR20220012281A (sr)
CN (1) CN113795255A (sr)
AU (2) AU2020280272B2 (sr)
BR (1) BR112021022602A2 (sr)
CA (1) CA3138081A1 (sr)
CL (1) CL2021003032A1 (sr)
DK (1) DK3972604T3 (sr)
ES (1) ES3039974T3 (sr)
FI (1) FI3972604T3 (sr)
HR (1) HRP20251001T1 (sr)
IL (1) IL286983B2 (sr)
LT (1) LT3972604T (sr)
MX (2) MX2021013942A (sr)
PL (1) PL3972604T3 (sr)
PT (1) PT3972604T (sr)
RS (1) RS67141B1 (sr)
SI (1) SI3972604T1 (sr)
TW (1) TWI868139B (sr)
WO (1) WO2020234782A1 (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3972604T3 (fi) * 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa

Also Published As

Publication number Publication date
AU2025252618A1 (en) 2025-11-06
TW202537625A (zh) 2025-10-01
IL286983B1 (en) 2025-09-01
HRP20251001T1 (hr) 2025-10-24
LT3972604T (lt) 2025-09-10
TWI868139B (zh) 2025-01-01
CN113795255A (zh) 2021-12-14
BR112021022602A2 (pt) 2022-01-04
DK3972604T3 (da) 2025-09-15
PL3972604T3 (pl) 2025-09-22
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
IL286983A (en) 2021-12-01
TW202110450A (zh) 2021-03-16
AU2020280272A1 (en) 2021-11-18
ES3039974T3 (en) 2025-10-28
SI3972604T1 (sl) 2025-09-30
JP7568651B2 (ja) 2024-10-16
EP3972604A1 (en) 2022-03-30
CL2021003032A1 (es) 2022-09-09
US20220184074A1 (en) 2022-06-16
AU2020280272B2 (en) 2025-07-24
FI3972604T3 (fi) 2025-09-01
EP4599894A2 (en) 2025-08-13
KR20220012281A (ko) 2022-02-03
CA3138081A1 (en) 2020-11-26
EP4599894A3 (en) 2025-11-12
JP2024178168A (ja) 2024-12-24
US12419889B2 (en) 2025-09-23
WO2020234782A1 (en) 2020-11-26
EP3972604B1 (en) 2025-06-04
PT3972604T (pt) 2025-08-26
MX2021013942A (es) 2022-01-04
MX2024014626A (es) 2025-01-09
US20250375446A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
SI3972604T1 (sl) Brutonov zaviralec tirozin kinaze za zdravljenje kronične spontane urtikarije
IL282270A (en) An Aurora A kinase inhibitor for use in the treatment of neuroblastoma
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
SI3972603T1 (sl) Postopki zdravljenja sjogrenovega sindroma z uporabo zaviralca brutonove tirozin kinaze
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
IL255831A (en) Inhibitors of bruton's tyrosine kinase
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
IL261249A (en) Dosage preparations containing Bruton's tyrosine kinase inhibitor
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
IL285136A (en) bay1895344 kinase atr inhibitor for use in the treatment of hyperproliferative disease
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
WO2016109217A3 (en) Btk inhibitors
IL264341A (en) Succinate forms and preparations of proton tyrosine kinase inhibitors
EP3328380A4 (en) INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
IL283654A (en) Decarboxylase inhibitors for the treatment of Parkinson's disease
ZA202102274B (en) Use of casein kinase 1 inhibitors for treating vascular diseases
IL288924A (en) Casein kinase 1 inhibitors for use in the treatment of diseases associated with the expression of dux4 such as muscular dystrophy and cancer
IL284916A (en) Cyclic molecules as Bruton's tyrosine kinase inhibitors
PL3846788T3 (pl) Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona
IL292596A (en) Use of Janus kinase inhibitor and telomerase inhibitor to treat myeloproliferative tumor
IL292882B1 (en) Bruton's tyrosine kinase inhibitor dosage
PL4072532T3 (pl) Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie
EP4069689A4 (en) SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS
MA55964A (fr) Agents inhibiteurs de la tyrosine kinase de bruton